Der påvistes en tydelig nedsættelse af urinmarkørerne for knogleresorption (pyridinolin og deoxypyridinolin) hos patienterne behandlet med Bondronat, hvilket var statistisk signifikant i forhold til placebo.
There was a marked depression of urinary markers of bone resorption (pyridinoline and deoxypyridinoline) in patients treated with Bondronat that was statistically significant compared to placebo.